Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

administered once every three weeks. The most common adverse events reported thus far include nausea, fatigue, vomiting and alopecia. There was a low rate of febrile neutropenia or other Grade 3/4 adverse events, and manageable Grade 1/2 nausea or vomiting.

Based on the indications of clinical activity and the acceptable tolerability profile demonstrated to date among this patient population, the dose of SNS-595 in this trial has been increased to 60 mg/m2 over twenty-eight days. Patient accrual at this dose level is ongoing.

"We are pleased by the strong signal of activity emerging from our Phase 2 clinical trial of SNS-595 at the 48mg/m2 dose level. Based on the drug's observed safety profile and recommendations from advisors, we are exploring a higher dose of SNS-595 in this trial. Enrollment has begun at 60 mg/m2 and we expect to enroll approximately 30 patients at this dose by the third quarter of this year," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Enthusiasm for SNS-595 among our clinical investigators is growing and enrollment in this trial has been accelerating. We expect to present further data from this Phase 2 clinical trial this year."

The interim clinical results are being presented in a poster, "A Phase 2 Trial of SNS-595 in Women with Platinum-Refractory Epithelial Ovarian Cancer" (Abstract # 290), at the 39th Annual Meeting on Women's Cancer hosted by the Society of Gynecologic Oncologists (SGO) in Tampa, Fla. through March 12, 2008.

About SNS-595

SNS-595 is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double strand DNA damage, irreversible G2 arrest and rapid apoptosis. In non-clinical evaluations, SNS-595 demonstrates broad and potent a
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... participate in the inaugural Tweetchat taking place in ... Worldwide , organised by UBM Live , ... #CPhIChat is a first of its kind global ... across the supply chain, aimed to stimulate conversations ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces ... available in its catalogue: Needle-Free ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... technological and commercial prospects What does the ... Visiongain,s brand new report shows you the ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Reimbursement Landscape Poland " an essential source of ... healthcare market and provides insights into the demographic, ... the report provides valuable insights into the trends ...
Breaking Medicine Technology:CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... SAN DIEGO and SUNNYVALE, Calif., April 16 ,Pharmacyclics, ... results,demonstrating the anti-tumor activity of PCI-27483, the company,s,small-molecule ... the,Annual Meeting of the American Association for Cancer ... CA., Researchers reported that in animal models ...
... April 16, 2008 A new Mayo,Clinic study ... against,mild cognitive impairment, a disorder of the brain ... study will be presented at the,American Academy of ... Individuals with mild cognitive impairment can function ...
Cached Medicine Technology:Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer 2Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer 3Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 2
(Date:8/29/2014)... 2 PM US Eastern Time)The current method to ... commonly produced in animals, to neutralize the toxin. ... to difficulties in developing, producing and maintaining the ... led by Charles Shoemaker, Ph.D., professor in the ... the Cummings School of Veterinary Medicine at Tufts ...
(Date:8/29/2014)... AB A new study from the research group of ... and the Lawson Health Research Institute (London, ON) has confirmed ... cancer. The study, published in Cell Reports , shows ... of cancer entirely. , Roughly 2 in 5 Canadians ... of them will die of the disease. In 2014, it,s ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
(Date:8/29/2014)... Honey Gifts, premium Vancouver adult toys retailer, has ... purse-sized adult toys and erotic products. These products are ... carried in a woman’s purse with complete ease. Not ... Gifts is also leak-free and will not make a ... common characteristics of Honey Gifts’ portable toys range. As ...
(Date:8/29/2014)... 2014 Sansego is an ... interactive online community, and a range of personalized coaching ... the way to professional athletes. Crowie has brought together ... with him throughout the majority of his triathlon career. ... the triathlon public. , Sansego provides the following:, ...
Breaking Medicine News(10 mins):Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3
... , , ... CVS ) announced today that it has named Andrew ... the company,s retail-based health clinic subsidiary, and as Senior Vice President/Associate ... Dr. Sussman will be responsible for all clinical services and daily ...
... , PASO ROBLES, Calif., July 28 ... California, will make silicone micro-implants such as surgical drains, catheter ... not routine is the incredibly precise tolerances demanded of these ... achieving consistently precise results to within .001 inch is no ...
... , , New ... organizations , , WASHINGTON, July ... ability to show employers and purchasers that their on-going business ... help health care management companies achieve accreditation, URAC ...
... , MAITLAND, Fla. , July 28 ... treatment for infants with plagiocephaly and other head shape abnormalities, opened ... The Center currently also has offices in the Baltimore and Dallas ... orthoses, also commonly referred to as a cranial helmets or headbands. ...
... , , HOUSTON, July 28 ... finds that Houston Northwest Medical Center has received a Five-Star Rating ... for Bariatric Surgery in 2009/2010. , , HealthGrades ... American Hospitals Study, which analyzes patient outcomes for the most ...
... HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ -- China ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... China ("PRC"), today announced that the,Company is scheduled to ... in early August, 2009. , ...
Cached Medicine News:Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 2Health News:CVS Caremark Names Andrew J. Sussman, M.D., as President/Chief Operating Officer of MinuteClinic 3Health News:When You Make Things That Get Implanted in People, Small Things Count 2Health News:URAC Launches New eLearning Courses for Health Care Management Accreditation 2Health News:URAC Launches New eLearning Courses for Health Care Management Accreditation 3Health News:URAC Launches New eLearning Courses for Health Care Management Accreditation 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5Health News:Houston Northwest Medical Center's Bariatric Program Rated Top 15% in the Nation by HealthGrades 2Health News:Houston Northwest Medical Center's Bariatric Program Rated Top 15% in the Nation by HealthGrades 3Health News:China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: